Current liabilities increased 49.9%
Current liabilities changed +49.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current liabilities changed +49.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Trade receivables changed +43.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +46.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Shares outstanding changed +399.0% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Operating margin changed -741 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating income changed -32.7% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital changed -767.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change.
Free-cash-flow proxy changed +29.4% from the comparable as-filed period.
Gross margin changed -678 basis points from the comparable as-filed period.
Working capital / assets changed -1271 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Current ratio changed -32.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed -44.8% from the comparable as-filed period.
Cost of revenue changed +56.5% from the comparable as-filed period.
Revenue changed +20.5% from the comparable as-filed period.
Research & development changed +27.5% from the comparable as-filed period.
Capex / revenue changed -468 basis points from the comparable as-filed period.
Capital expenditure changed -61.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Receivables / revenue changed +868 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating cash-flow margin changed -343 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +28.0% from the comparable as-filed period.
Operating cash flow / net income changed +87.0% from the comparable as-filed period.
Cash & equivalents changed -12.2% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
SBC / revenue changed +90 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating cash flow changed +3.2% from the comparable as-filed period.
Gross profit changed +10.0% from the comparable as-filed period.
R&D / revenue changed +127 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Free-cash-flow margin changed +125 basis points from the comparable as-filed period.
Current assets changed +1.4% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating income changed -54.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Gross margin changed -680 basis points from the comparable as-filed period.
Operating margin changed -707 basis points from the comparable as-filed period.
Revenue changed +24.0% from the comparable as-filed period.
Net income changed -22.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -19.9% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed +24.7% from the comparable as-filed period.
Gross profit changed +13.1% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.